Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients.
Identifieur interne : 000C33 ( Main/Exploration ); précédent : 000C32; suivant : 000C34Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients.
Auteurs : RBID : pubmed:22018594English descriptors
- KwdEn :
- Adrenal Gland Neoplasms (drug therapy), Adrenal Gland Neoplasms (mortality), Adrenal Gland Neoplasms (secondary), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bone Neoplasms (drug therapy), Bone Neoplasms (mortality), Bone Neoplasms (secondary), Brain Neoplasms (drug therapy), Brain Neoplasms (mortality), Brain Neoplasms (secondary), Carboplatin (administration & dosage), Enzyme-Linked Immunosorbent Assay, Feasibility Studies, Female, Follow-Up Studies, Humans, Liver Neoplasms (drug therapy), Liver Neoplasms (mortality), Liver Neoplasms (secondary), Lung Neoplasms (drug therapy), Lung Neoplasms (mortality), Lung Neoplasms (pathology), Male, Middle Aged, Neoplasm Staging, Octreotide (analogs & derivatives), Octreotide (diagnostic use), Paclitaxel (administration & dosage), Peptides, Cyclic (administration & dosage), Prognosis, Receptors, Somatostatin (metabolism), Small Cell Lung Carcinoma (drug therapy), Small Cell Lung Carcinoma (mortality), Small Cell Lung Carcinoma (pathology), Somatostatin (administration & dosage), Somatostatin (analogs & derivatives), Survival Rate, Tumor Markers, Biological (metabolism).
- MESH :
- chemical , administration & dosage : Carboplatin, Paclitaxel, Peptides, Cyclic, Somatostatin.
- chemical , analogs & derivatives : Octreotide, Somatostatin.
- chemical , diagnostic use : Octreotide.
- drug therapy : Adrenal Gland Neoplasms, Bone Neoplasms, Brain Neoplasms, Liver Neoplasms, Lung Neoplasms, Small Cell Lung Carcinoma.
- chemical , metabolism : Receptors, Somatostatin, Tumor Markers, Biological.
- mortality : Adrenal Gland Neoplasms, Bone Neoplasms, Brain Neoplasms, Liver Neoplasms, Lung Neoplasms, Small Cell Lung Carcinoma.
- pathology : Lung Neoplasms, Small Cell Lung Carcinoma.
- secondary : Adrenal Gland Neoplasms, Bone Neoplasms, Brain Neoplasms, Liver Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Enzyme-Linked Immunosorbent Assay, Feasibility Studies, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Survival Rate.
Abstract
Long acting somatostatin analogues combined with platinum analogues have demonstrated an antiproliferative effect on growth of human SCLC xenographs.
DOI: 10.1016/j.lungcan.2011.09.014
PubMed: 22018594
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients.</title><author><name sortKey="Zarogoulidis, K" uniqKey="Zarogoulidis K">K Zarogoulidis</name><affiliation wicri:level="1"><nlm:affiliation>Lung Tumour Research Section, Pulmonary Department, Aristotle University Pulmonary Clinic, G. Papanikolaou Hospital, Exohi, Thessaloniki, Greece. zarog@med.auth.gr</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Lung Tumour Research Section, Pulmonary Department, Aristotle University Pulmonary Clinic, G. Papanikolaou Hospital, Exohi, Thessaloniki</wicri:regionArea></affiliation></author><author><name sortKey="Eleftheriadou, E" uniqKey="Eleftheriadou E">E Eleftheriadou</name></author><author><name sortKey="Kontakiotis, Th" uniqKey="Kontakiotis T">Th Kontakiotis</name></author><author><name sortKey="Gerasimou, G" uniqKey="Gerasimou G">G Gerasimou</name></author><author><name sortKey="Zarogoulidis, P" uniqKey="Zarogoulidis P">P Zarogoulidis</name></author><author><name sortKey="Sapardanis, I" uniqKey="Sapardanis I">I Sapardanis</name></author><author><name sortKey="Galaktidou, G" uniqKey="Galaktidou G">G Galaktidou</name></author><author><name sortKey="Sakkas, L" uniqKey="Sakkas L">L Sakkas</name></author><author><name sortKey="Gotzamani Psarrakou, A" uniqKey="Gotzamani Psarrakou A">A Gotzamani-Psarrakou</name></author><author><name sortKey="Karatzas, N" uniqKey="Karatzas N">N Karatzas</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.1016/j.lungcan.2011.09.014</idno><idno type="RBID">pubmed:22018594</idno><idno type="pmid">22018594</idno><idno type="wicri:Area/Main/Corpus">001102</idno><idno type="wicri:Area/Main/Curation">001102</idno><idno type="wicri:Area/Main/Exploration">000C33</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Gland Neoplasms (drug therapy)</term><term>Adrenal Gland Neoplasms (mortality)</term><term>Adrenal Gland Neoplasms (secondary)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Bone Neoplasms (drug therapy)</term><term>Bone Neoplasms (mortality)</term><term>Bone Neoplasms (secondary)</term><term>Brain Neoplasms (drug therapy)</term><term>Brain Neoplasms (mortality)</term><term>Brain Neoplasms (secondary)</term><term>Carboplatin (administration & dosage)</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Feasibility Studies</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Liver Neoplasms (drug therapy)</term><term>Liver Neoplasms (mortality)</term><term>Liver Neoplasms (secondary)</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (mortality)</term><term>Lung Neoplasms (pathology)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (diagnostic use)</term><term>Paclitaxel (administration & dosage)</term><term>Peptides, Cyclic (administration & dosage)</term><term>Prognosis</term><term>Receptors, Somatostatin (metabolism)</term><term>Small Cell Lung Carcinoma (drug therapy)</term><term>Small Cell Lung Carcinoma (mortality)</term><term>Small Cell Lung Carcinoma (pathology)</term><term>Somatostatin (administration & dosage)</term><term>Somatostatin (analogs & derivatives)</term><term>Survival Rate</term><term>Tumor Markers, Biological (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carboplatin</term><term>Paclitaxel</term><term>Peptides, Cyclic</term><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adrenal Gland Neoplasms</term><term>Bone Neoplasms</term><term>Brain Neoplasms</term><term>Liver Neoplasms</term><term>Lung Neoplasms</term><term>Small Cell Lung Carcinoma</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Somatostatin</term><term>Tumor Markers, Biological</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Adrenal Gland Neoplasms</term><term>Bone Neoplasms</term><term>Brain Neoplasms</term><term>Liver Neoplasms</term><term>Lung Neoplasms</term><term>Small Cell Lung Carcinoma</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung Neoplasms</term><term>Small Cell Lung Carcinoma</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Adrenal Gland Neoplasms</term><term>Bone Neoplasms</term><term>Brain Neoplasms</term><term>Liver Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Enzyme-Linked Immunosorbent Assay</term><term>Feasibility Studies</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Survival Rate</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Long acting somatostatin analogues combined with platinum analogues have demonstrated an antiproliferative effect on growth of human SCLC xenographs.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22018594</PMID><DateCreated><Year>2012</Year><Month>03</Month><Day>12</Day></DateCreated><DateCompleted><Year>2012</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8332</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lung cancer (Amsterdam, Netherlands)</Title><ISOAbbreviation>Lung Cancer</ISOAbbreviation></Journal><ArticleTitle>Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients.</ArticleTitle><Pagination><MedlinePgn>84-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lungcan.2011.09.014</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long acting somatostatin analogues combined with platinum analogues have demonstrated an antiproliferative effect on growth of human SCLC xenographs.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">130 previously untreated SCLC patients--54 with limited disease (LD) and positive somatostatin receptors were included in the study. All patients performed 111In-Octreotide scanning before chemotherapy (CHT), every 3 months and up to 4 times. All patients were treated with paclitaxel 190 mg/m2+carboplatin AUC=5.5 for up to 6 cycles. 47/130 patients (Group A, control group) received only CHT. Forty eight hours after each CHT 43/130 patients (Group B) were also administered 30 mg somatuline® (lanreotide) by a single subcutaneous (s.c.) injection to stimulate somatostatin receptors (SSTRS) for 2 weeks. 40/130 patients (Group C) received 60 mg somatuline® autogel to stimulate SSTRS for 4 weeks. Patients in Groups A and B after the completion of the CHT continued maintenance therapy with somatuline. NSE, IGF1, VEGFA, VEGFC, VEGFR2, HER2 levels were monitored. In histological samples Bcl-2 and VEGF were also explored by immunohistochemistry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No statistically significant differences were observed between the 3 Groups regarding LD and extensive disease (ED) patient ratios, age and PS. Group B had a survival benefit in comparison to Groups A and C (p=0.029). LD patients of Group B had a significant benefit compared to Groups A and C (p=0.012, Breslow test). In LD Group B had a significant longer TTP (p=0.02) in comparison to Groups A and C. Adverse effects had no statistically significant difference between the Groups and toxicity was well managed.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Long acting somatostatin analogues could be used as an additive therapy in combination to antineoplastic agents in patients positive for somatostatin receptors. A dose of 30 mg improved survival only in LD SCLC patients.</AbstractText><CopyrightInformation>Crown Copyright © 2011. Published by Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zarogoulidis</LastName><ForeName>K</ForeName><Initials>K</Initials><Affiliation>Lung Tumour Research Section, Pulmonary Department, Aristotle University Pulmonary Clinic, G. Papanikolaou Hospital, Exohi, Thessaloniki, Greece. zarog@med.auth.gr</Affiliation></Author><Author ValidYN="Y"><LastName>Eleftheriadou</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kontakiotis</LastName><ForeName>Th</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Gerasimou</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Zarogoulidis</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sapardanis</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Galaktidou</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sakkas</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Gotzamani-Psarrakou</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Karatzas</LastName><ForeName>N</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial, Phase II</PublicationType><PublicationType>Clinical Trial, Phase III</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Lung Cancer</MedlineTA><NlmUniqueID>8800805</NlmUniqueID><ISSNLinking>0169-5002</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Peptides, Cyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Tumor Markers, Biological</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>indium-111-octreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>118992-92-0</RegistryNumber><NameOfSubstance>lanreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>33069-62-4</RegistryNumber><NameOfSubstance>Paclitaxel</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance>Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>BG3F62OND5</RegistryNumber><NameOfSubstance>Carboplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adrenal Gland Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">drug therapy</QualifierName><QualifierName MajorTopicYN="N">mortality</QualifierName><QualifierName MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Bone Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">drug therapy</QualifierName><QualifierName MajorTopicYN="N">mortality</QualifierName><QualifierName MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Brain Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">drug therapy</QualifierName><QualifierName MajorTopicYN="N">mortality</QualifierName><QualifierName MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carboplatin</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">drug therapy</QualifierName><QualifierName MajorTopicYN="N">mortality</QualifierName><QualifierName MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">drug therapy</QualifierName><QualifierName MajorTopicYN="N">mortality</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Peptides, Cyclic</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Small Cell Lung Carcinoma</DescriptorName><QualifierName MajorTopicYN="Y">drug therapy</QualifierName><QualifierName MajorTopicYN="N">mortality</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName><QualifierName MajorTopicYN="N">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tumor Markers, Biological</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S0169-5002(11)00483-1</ArticleId><ArticleId IdType="doi">10.1016/j.lungcan.2011.09.014</ArticleId><ArticleId IdType="pubmed">22018594</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22018594
|texte= Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22018594" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |